{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:21:51Z","timestamp":1793848911079,"version":"4.6.1"},"reference-count":318,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Neurodegenerative disorders including Alzheimer\u2019s, Parkinson\u2019s, and dementia are chronic and advanced diseases that are associated with loss of neurons and other related pathologies. Furthermore, these disorders involve structural and functional defections of the blood-brain barrier (BBB). Consequently, advances in medicines and therapeutics have led to a better appreciation of various pathways associated with the development of neurodegenerative disorders, thus focusing on drug discovery and research for targeted drug therapy to the central nervous system (CNS). Although the BBB functions as a shield to prevent toxins in the blood from reaching the brain, drug delivery to the CNS is hindered by its presence. Owing to this, various formulation approaches, including the use of lipid-based nanocarriers, have been proposed to address shortcomings related to BBB permeation in CNS-targeted therapy, thus showing the potential of these carriers for translation into clinical use. Nevertheless, to date, none of these nanocarriers has been granted market authorization following the successful completion of all stages of clinical trials. While the aforementioned benefits of using lipid-based carriers underscores the need to fast-track their translational development into clinical practice, technological advances need to be initiated to achieve appropriate capacity for scale-up and the production of affordable dosage forms.<\/jats:p>","DOI":"10.3390\/pharmaceutics14040836","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T02:48:59Z","timestamp":1649731739000},"page":"836","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-9368","authenticated-orcid":false,"given":"Bwalya Angel","family":"Witika","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0208, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7289-3408","authenticated-orcid":false,"given":"Madan Sai","family":"Poka","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0208, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Hulisani","family":"Demana","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria 0208, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-7039","authenticated-orcid":false,"given":"Scott Kaba","family":"Matafwali","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyabonga","family":"Melamane","sequence":"additional","affiliation":[{"name":"Stutterheim Hospital, No.1 Hospital Street, Stutterheim 4930, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandile Maswazi","family":"Malungelo Khamanga","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics, Faculty of Pharmacy, Rhodes University, Makhanda 6140, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8475-447X","authenticated-orcid":false,"given":"Pedzisai Anotida","family":"Makoni","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Faculty of Pharmacy, Rhodes University, Makhanda 6140, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/03602532.2020.1726942","article-title":"Lipid-based nanoformulations in the treatment of neurological disorders","volume":"52","author":"Pottoo","year":"2020","journal-title":"Drug Metab. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1871524914666141030145948","article-title":"Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances","volume":"14","author":"Goyal","year":"2014","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijpharm.2012.06.025","article-title":"Drug delivery strategies for the treatment of malignant gliomas","volume":"436","author":"Allhenn","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/157488912798842241","article-title":"Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery","volume":"7","author":"Micheli","year":"2012","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2019.12.014","article-title":"Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer\u2019s disease","volume":"148","author":"Akel","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e07994","DOI":"10.1016\/j.heliyon.2021.e07994","article-title":"Lipid nanostructures for targeting brain cancer","volume":"7","author":"Nsairat","year":"2021","journal-title":"Heliyon"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ali, O.A.M.A., Shaikh, M.F., Hasnain, M.S., Sami, F., Khan, A., and Ansari, M.T. (2021). Nanotechnological Advances in the Treatment of Epilepsy. CNS Neurol. Disord. Drug Targets, 21, E-pub Ahead of Print.","DOI":"10.2174\/1871527321666211221162104"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Shilpi, S., Jain, A., Dixit, S., Saraogi, G., Yadav, A.K., and Jain, S.K. (2022). Lipid nanocarrier-based drug delivery for the treatment of brain-related disorders. Nanomedical Drug Delivery for Neurodegenerative Diseases, Academic Press.","DOI":"10.1016\/B978-0-323-85544-0.00014-9"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s11064-021-03488-7","article-title":"Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders","volume":"47","author":"Nguyen","year":"2022","journal-title":"Neurochem. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","article-title":"Drug targeting to the brain","volume":"24","author":"Pardridge","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zeiadeh, I., Najjar, A., and Karaman, R. (2018). Strategies for enhancing the permeation of cns-active drugs through the blood-brain barrier: A review. Molecules, 23.","DOI":"10.3390\/molecules23061289"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4137\/PMC.S13384","article-title":"Pathways for small molecule delivery to the central nervous system across the blood-brain barrier","volume":"6","author":"Mikitsh","year":"2014","journal-title":"Perspect. Medicin. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2018.10.004","article-title":"Recent progress of drug nanoformulations targeting to brain","volume":"291","author":"Khan","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","article-title":"The blood-brain and the blood-cerebrospinal fluid barriers: Function and dysfunction","volume":"31","author":"Engelhardt","year":"2009","journal-title":"Semin. Immunopathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.2174\/1568026614666140329230311","article-title":"Recent advances in delivery through the blood-brain barrier","volume":"14","author":"Larsen","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2174\/156802607782194806","article-title":"Mini review on molecular modeling of P-glycoprotein (Pgp)","volume":"7","author":"Ha","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The Blood-Brain Barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte\u2013endothelial interactions at the blood-brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"a002907","DOI":"10.1101\/cshperspect.a002907","article-title":"Molecular basis of the core structure of tight junctions","volume":"2","author":"Furuse","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e25247","DOI":"10.4161\/tisb.25247","article-title":"Claudin interactions in and out of the tight junction","volume":"1","author":"Anderson","year":"2013","journal-title":"Tissue Barriers"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.addr.2004.07.005","article-title":"The structure of the choroid plexus and the physiology of the choroid plexus epithelium","volume":"56","author":"Redzic","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/07420528.2017.1400978","article-title":"The choroid plexus harbors a circadian oscillator modulated by estrogens","volume":"35","author":"Quintela","year":"2017","journal-title":"Chronobiol. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e20190062","DOI":"10.1084\/jem.20190062","article-title":"The blood-brain barrier in health and disease: Important unanswered questions","volume":"217","author":"Profaci","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41423-021-00757-x","article-title":"The blood-brain barrier in systemic infection and inflammation","volume":"18","author":"Galea","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fnagi.2020.00185","article-title":"Dysfunction of the Blood-Brain Barrier\u2014A Key Step in Neurodegeneration and Dementia","volume":"12","author":"Noe","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Groblewska, M., and Mroczko, B. (2021). Pro-and antiangiogenic factors in gliomas: Implications for novel therapeutic possibilities. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116126"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: Causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fncel.2014.00418","article-title":"Gliomas and the vascular fragility of the blood brain barrier","volume":"8","author":"Dubois","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1152\/physrev.00019.2012","article-title":"Claudins and the modulation of tight junction permeability","volume":"93","author":"Yu","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3389\/fphys.2018.01942","article-title":"Tight junction proteins and signaling pathways in cancer and inflammation: A functional crosstalk","volume":"10","author":"Bhat","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"320941","DOI":"10.1155\/2015\/320941","article-title":"Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors","volume":"2015","author":"Bhowmik","year":"2015","journal-title":"Biomed Res. Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbamem.2008.11.005","article-title":"Loss of tight junction barrier function and its role in cancer metastasis","volume":"1788","author":"Martin","year":"2009","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4143\/crt.2006.38.3.139","article-title":"Occludin Expression in Brain Tumors and its Relevance to Peritumoral Edema and Survival","volume":"38","author":"Park","year":"2006","journal-title":"Cancer Res. Treat."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1369\/jhc.5A6870.2006","article-title":"In Situ Localization of P-glycoprotein (ABCB1) in Human and Rat Brain","volume":"54","author":"Bendayan","year":"2006","journal-title":"J. Histochem. Cytochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","article-title":"Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)","volume":"22","author":"Doyle","year":"2003","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2020.00265","article-title":"Perplexing Role of P-Glycoprotein in Tumor Microenvironment","volume":"10","author":"Robinson","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/j.1471-4159.1991.tb06411.x","article-title":"The susceptibility of cerebral endothelial cells to astroglial induction of blood-brain barrier enzymes depends on their proliferative state","volume":"57","author":"Meyer","year":"1991","journal-title":"J. Neurochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0006-2952(93)90139-N","article-title":"Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain","volume":"45","author":"Perrin","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2009.03.017","article-title":"Drug interactions at the blood-brain barrier: Fact or fantasy?","volume":"123","author":"Eyal","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/156802609787521580","article-title":"Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2)","volume":"9","author":"Nicolazzo","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejps.2016.05.008","article-title":"Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration","volume":"91","author":"Shah","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_46","unstructured":"Morton, D.A., Foreman, K.B., and Albertine, K.H. (2011). Nasal Cavity. The Big Picture: Gross Anatomy, McGraw-Hill Education."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lochhead, J.J., and David, T.P. (2019). Perivascular and perineural pathways involved in brain delivery and distribution of drugs after intranasal administration. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11110598"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: Mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1567201053586047","article-title":"Intranasal drug delivery for brain targeting","volume":"2","author":"Vyas","year":"2005","journal-title":"Curr. Drug Deliv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0361-9230(85)90129-7","article-title":"Transport of molecules from nose to brain: Transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium","volume":"15","author":"Shipley","year":"1985","journal-title":"Brain Res. Bull."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/cne.902420410","article-title":"Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo","volume":"242","author":"Broadwell","year":"1985","journal-title":"J. Comp. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4155\/tde.14.41","article-title":"The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview","volume":"5","author":"Djupesland","year":"2014","journal-title":"Ther. Deliv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0006-8993(77)90978-7","article-title":"The axonal projection patterns of the mitral and tufted cells of the olfactory bulb in the rat","volume":"129","author":"Haberly","year":"1977","journal-title":"Brain Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0306-4522(85)90152-6","article-title":"A comparison between wheat germ agglutinin- and choleragenoid-horseradish peroxidase as anterogradely transported markers in central branches of primary sensory neurones in the rat with some observations in the cat","volume":"14","author":"Robertson","year":"1985","journal-title":"Neuroscience"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cne.901590206","article-title":"Demonstration of terminalis, olfactory, trigeminal and perivascular nerves in the rat nasal septum","volume":"159","year":"1975","journal-title":"J. Comp. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/cancers5031020","article-title":"Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?","volume":"5","author":"Wauthoz","year":"2013","journal-title":"Cancers"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1208\/s12249-011-9614-1","article-title":"Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution","volume":"12","author":"Hoekman","year":"2011","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cne.902510209","article-title":"Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey","volume":"251","author":"Balin","year":"1986","journal-title":"J. Comp. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11095-011-0641-0","article-title":"Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles","volume":"29","author":"Liu","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4684-3264-0_4","article-title":"The morphological approach to the study of normal and abnormal brain permeability","volume":"69","author":"Brightman","year":"1976","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Hong, S.S., Oh, K.T., Choi, H.G., and Lim, S.J. (2019). Liposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11100540"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: How, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","article-title":"A review of intranasal formulations for the treatment of seizure emergencies","volume":"237","author":"Kapoor","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_70","first-page":"454","article-title":"Nasal drug delivery system\u2014An overview","volume":"1","author":"Alagusundaram","year":"2010","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2174\/1389200217666160406120509","article-title":"Drug-metabo-lizing enzymes and efflux transporters in nasal epithelium: Influence on the bioavailability of intranasally adminis-tered drugs","volume":"17","author":"Oliveira","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/03602532.2019.1632890","article-title":"Nasal odorant metabolism: Enzymes, activity and function in olfaction","volume":"51","author":"Heydel","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/ar.22735","article-title":"Odorant-binding proteins and xenobiotic metabolizing enzymes: Implications in olfactory perireceptor events","volume":"296","author":"Heydel","year":"2013","journal-title":"Anat. Rec."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1023\/A:1015830907632","article-title":"The nasal mucociliary clearance: Relevance to nasal drug delivery","volume":"8","author":"Schipper","year":"1991","journal-title":"Pharm. Res."},{"key":"ref_75","first-page":"19","article-title":"Nasal drug delivery: An overview","volume":"6","author":"Mundlia","year":"2015","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"ref_76","first-page":"6","article-title":"Nanoemulsion based intranasal delivery of risperidone for nose to brain targeting","volume":"5","author":"Prajapati","year":"2015","journal-title":"Bull. Pharm. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1111\/j.1528-1157.1999.tb02088.x","article-title":"The Clinical Pharmacokinetics of the New Antiepileptic Drugs","volume":"40","author":"Perucca","year":"1999","journal-title":"Epilepsia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/10611869909085506","article-title":"Transnasal delivery of 5-fluorouracil to the brain in the rat","volume":"7","author":"Sakane","year":"1999","journal-title":"J. Drug Target."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.xphs.2019.03.006","article-title":"The Hypotonic Environmental Changes Affect Liposomal Formulations for Nose-to-Brain Targeted Drug Delivery","volume":"108","author":"Wu","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jconrel.2018.12.049","article-title":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","volume":"295","author":"Costa","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_81","first-page":"47","article-title":"The deposition of aerosol particles in the nasopharyngeal region of the human respiratory tract","volume":"1","author":"Hounam","year":"1970","journal-title":"Inhaled Part"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/archinte.1973.00320070128014","article-title":"Clearance of inhaled particle from human nose","volume":"131","author":"Proctor","year":"1973","journal-title":"Arch. Intern. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/bies.950171213","article-title":"Surrogate Cells or Trojan Horses: The Discovery of Liposomes","volume":"17","author":"Bangham","year":"1995","journal-title":"BioEssays"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"IN26","DOI":"10.1016\/S0022-2836(65)80093-6","article-title":"Diffusion of univalent ions across the lamellae of swollen phospholipids","volume":"13","author":"Bangham","year":"1965","journal-title":"J. Mol. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/0250-474X.25707","article-title":"Vesicular systems: An overview","volume":"68","author":"Talegaonkar","year":"2006","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/00003495-199856050-00001","article-title":"Liposomal drug formulations. Rationale for development and what we can expect for the future","volume":"56","author":"Allen","year":"1998","journal-title":"Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Catala, A. (2019). General Perception of Liposomes: Formation, Manufacturing and sApplications. Liposomes\u2014Advances and Perspectives, IntechOpen.","DOI":"10.5772\/intechopen.77926"},{"key":"ref_88","unstructured":"Witika, B.A. (2017). The Development, Manufacture and Characterisation of Niosomes Intended to Deliver Nevirapine to the Brain. [Master\u2019s Thesis, Rhodes University]."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1208\/s12249-008-9105-1","article-title":"Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery","volume":"9","author":"Abdelbary","year":"2008","journal-title":"AAPS PharmSciTech"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijpharm.2008.05.031","article-title":"Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes","volume":"361","author":"Mokhtar","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0076-6879(05)91019-7","article-title":"Lymphoid tissue targeting of anti-HIV drugs using liposomes","volume":"391","author":"Bergeron","year":"2005","journal-title":"Methods Enzymol."},{"key":"ref_92","first-page":"79","article-title":"Development of liposomal formulations: From concept to clinical investigations","volume":"8","author":"Fan","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-00477-3_1","article-title":"Passive and active drug targeting: Drug delivery to tumors as an example","volume":"Volume 197","author":"Torchilin","year":"2010","journal-title":"Handbook of Experimental Pharmacology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s13204-018-0776-y","article-title":"Conjugation of isoniazid to a zinc phthalocyanine via hydrazone linkage for pH-dependent liposomal controlled release","volume":"8","author":"Nkanga","year":"2018","journal-title":"Appl. Nanosci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1166\/jbn.2020.2880","article-title":"Co-loading of isoniazid-grafted phthalocyanine-in-cyclodextrin and rifampicin in crude soybean lecithin liposomes: Formulation, spectroscopic and biological characterization","volume":"16","author":"Nkanga","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijpharm.2017.04.074","article-title":"Preparation and characterization of isoniazid-loaded crude soybean lecithin liposomes","volume":"526","author":"Nkanga","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Wagner, A., and Vorauer-Uhl, K. (2011). Liposome Technology for Industrial Purposes, Informa Healthcare Inc.. [3rd ed.].","DOI":"10.1155\/2011\/591325"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0167-5699(90)90034-7","article-title":"Immunological adjuvants: A role for liposomes","volume":"11","author":"Gregoriadis","year":"1990","journal-title":"Immunol. Today"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/17425240902967607","article-title":"Pharmacosomes: The lipid-based new drug delivery system","volume":"6","author":"Semalty","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S1176","DOI":"10.1016\/S2221-1691(12)60381-5","article-title":"Recent advances in various emerging vescicular systems: An overview","volume":"2","author":"Gangwar","year":"2012","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"ref_101","first-page":"90","article-title":"Pharmacosomes: A Potential Vesicular Drug Delivery System","volume":"6","author":"Venkatesh","year":"2014","journal-title":"Int. J. Pharm. Sci. Drug Res."},{"key":"ref_102","first-page":"348186","article-title":"Pharmacosomes: An Emerging Novel Vesicular Drug Delivery System for Poorly Soluble Synthetic and Herbal Drugs","volume":"2013","author":"Pandita","year":"2013","journal-title":"ISRN Pharm."},{"key":"ref_103","first-page":"25","article-title":"Pharmacosomes: Opening new doors for drug delivery","volume":"4","author":"Goyal","year":"2012","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_104","first-page":"168","article-title":"Pharmacosomes: An emerging vesicular system","volume":"5","author":"Kavitha","year":"2010","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2478\/v10007-009-0023-x","article-title":"Development and physicochemical evaluation of pharmacosomes of diclofenac","volume":"59","author":"Semalty","year":"2009","journal-title":"Acta Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4103\/0250-474X.78523","article-title":"Development and Evaluation of Pharmacosomes of Aceclofenac","volume":"72","author":"Semalty","year":"2010","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/21691401.2014.883401","article-title":"Vesicular system: Versatile carrier for transdermal delivery of bioactives","volume":"43","author":"Singh","year":"2015","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.apsb.2011.09.002","article-title":"Nonionic surfactant vesicular systems for effective drug delivery\u2014an overview","volume":"1","author":"Kumar","year":"2011","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0168-3659(95)00056-E","article-title":"Transdermal drug carriers: Basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides","volume":"36","author":"Cevc","year":"1995","journal-title":"J. Control. Release"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0005-2736(97)00177-6","article-title":"Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin","volume":"1368","author":"Cevc","year":"1998","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"119398","DOI":"10.1016\/j.ijpharm.2020.119398","article-title":"What\u2019s new in the field of phospholipid vesicular nanocarriers for skin drug delivery","volume":"583","author":"Lai","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_112","first-page":"435","article-title":"Transferosomes\u2014A Review","volume":"5","author":"Solanki","year":"2016","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0378-5173(99)00441-X","article-title":"Oestradiol skin delivery from ultradeformable liposomes: Refinement of surfactant concentration","volume":"196","author":"Williams","year":"2000","journal-title":"Int. J. Pharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-200342050-00004","article-title":"Transdermal drug delivery of insulin with ultradeformable carriers","volume":"42","author":"Cevc","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1773-2247(13)50089-X","article-title":"Formulation and evaluation of piroxicam transferosomal gel: An approach for penetration enhancement","volume":"23","author":"Ghanbarzadeh","year":"2013","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_116","first-page":"362","article-title":"Transfersomes: Self-optimizing carriers for bioactives","volume":"62","author":"Rai","year":"2008","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"ref_117","unstructured":"Ramsden, J.J. (2014). Applied Nanotechnology: The Conversion of Research Results to Products (Micro and Nano Technologies), Elsevier."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0005-2736(01)00369-8","article-title":"New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes","volume":"1514","author":"Cevc","year":"2001","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_119","first-page":"93","article-title":"Formulation and evaluation of diacerein cream","volume":"4","author":"Kumar","year":"2011","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-5173(01)00810-9","article-title":"Preparation and in vitro evaluation of liposomal\/niosomal delivery systems for antipsoriatic drug dithranol","volume":"228","author":"Agarwal","year":"2001","journal-title":"Int. J. Pharm."},{"key":"ref_121","first-page":"249","article-title":"Preparation and evaluation of niosomes containing aceclofenac","volume":"5","author":"Srinivas","year":"2010","journal-title":"Dig. J. Nanomater. Biostructures"},{"key":"ref_122","first-page":"1036","article-title":"Niosomes: A Novel Trend in Drug Delivery","volume":"3","author":"Shakya","year":"2014","journal-title":"Int. J. Res. Dev. Pharm. Life Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0378-5173(98)00169-0","article-title":"Non-ionic surfactant based vesicles (niosomes) in drug delivery","volume":"172","author":"Uchegbu","year":"1998","journal-title":"Int. J. Pharm."},{"key":"ref_124","first-page":"1019","article-title":"Distribution, Metabolism and Tumoricidal Activity of Doxorubicin Administered in Sorbitan Monostearate (Span 60) Niosomes in the Mouse","volume":"12","author":"Uchegbu","year":"1995","journal-title":"Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijpharm.2006.01.040","article-title":"Preparation and characteristics of monostearin nanostructured lipid carriers","volume":"314","author":"Hu","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.addr.2003.12.002","article-title":"Solid lipid nanoparticles for parenteral drug delivery","volume":"56","author":"Wissing","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles Production, characterization and applications","volume":"47","author":"Mehnert","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_128","first-page":"313","article-title":"Solid Lipid Nanoparticles and Nanostructured Lipid Carriers-Lipid Nanoparticles for Medicals and Pharmaceuticals","volume":"23","author":"Souto","year":"2011","journal-title":"Encycl. Nanosci. Nanotechnol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"Radtke","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014A review of the state of the art","volume":"50","author":"Gohla","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ejpb.2008.05.008","article-title":"Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC)","volume":"70","author":"Fang","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2004.02.032","article-title":"Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery","volume":"278","author":"Souto","year":"2004","journal-title":"Int. J. Pharm."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","article-title":"Nanostructured lipid matrices for improved microencapsulation of drugs","volume":"242","author":"Radtke","year":"2002","journal-title":"Int. J. Pharm."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-409X(01)00108-9","article-title":"Cubic phase gels as drug delivery systems","volume":"47","author":"Shah","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cis.2006.06.016","article-title":"Thermodynamic and kinetic aspects of fat crystallization","volume":"122","author":"Himawan","year":"2006","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.addr.2007.04.012","article-title":"Nanostructured lipid carriers (NLC) in cosmetic dermal products","volume":"59","author":"Petersen","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_137","first-page":"36","article-title":"Comparative study between the viscoelastic behaviors of different lipid nanoparticle formulations","volume":"55","author":"Souto","year":"2004","journal-title":"Int. J. Cosmet. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(99)00223-0","article-title":"Vitamin A-loaded solid lipid nanoparticles for topical use: Drug release properties","volume":"66","author":"Jenning","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.6b01027","article-title":"Lipid-Drug Conjugate for Enhancing Drug Delivery","volume":"14","author":"Irby","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.2174\/1381612826666200311124003","article-title":"Lipid Drug Conjugates for Improved Therapeutic Benefits","volume":"26","author":"Shrivastava","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Mouzouvi, C.R.A., Umerska, A., Bigot, A.K., and Saulnier, P. (2017). Surface active properties of lipid nanocapsules. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179211"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpharm.2016.02.019","article-title":"Lipid-based nanoformulations for peptide delivery","volume":"502","author":"Matougui","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1023\/A:1016121319668","article-title":"A Novel Phase Inversion-Based Process for the Preparation of Lipid Nanocarriers","volume":"19","author":"Heurtault","year":"2002","journal-title":"Pharm. Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-407173-5.00002-9","article-title":"Bioengineering Strategies for Designing Targeted Cancer Therapies","volume":"118","author":"Wen","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.addr.2008.03.008","article-title":"Micelles and nanoparticles for ultrasonic drug and gene delivery","volume":"60","author":"Husseini","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jconrel.2005.09.034","article-title":"Block copolymer micelles: Preparation, characterization and application in drug delivery","volume":"109","author":"Gaucher","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0168-3659(99)00242-4","article-title":"Inner core segment design for drug delivery control of thermo-responsive polymeric micelles","volume":"65","author":"Chung","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(99)00029-2","article-title":"Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly(N-isopropylacrylamide) and poly(butylmethacrylate)","volume":"62","author":"Chung","year":"1999","journal-title":"J. Control. Release"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0168-3659(97)00244-7","article-title":"Effect of molecular architecture of hydrophobically modified poly(N-isopropylacrylamide) on the formation of thermoresponsive core-shell micellar drug carriers","volume":"53","author":"Chung","year":"1998","journal-title":"J. Control. Release"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/nnm.10.126","article-title":"Self-nanoemulsifying drug delivery systems: Formulation insights, applications and advances","volume":"5","author":"Date","year":"2010","journal-title":"Nanomedicine"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3746\/pnf.2019.24.3.225","article-title":"Techniques for Formulation of Nanoemulsion Drug Delivery System: A Review","volume":"24","author":"Kumar","year":"2019","journal-title":"Prev. Nutr. Food Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.colsurfa.2017.10.076","article-title":"Production, properties, and applications of solid self-emulsifying delivery systems (S-SEDS) in the food and pharmaceutical industries","volume":"538","author":"Nikmaram","year":"2018","journal-title":"Colloids Surfaces A Physicochem. Eng. Asp."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/1541-4337.12189","article-title":"Formation of Food-Grade Nanoemulsions Using Low-Energy Preparation Methods: A Review of Available Methods","volume":"15","author":"Komaiko","year":"2016","journal-title":"Compr. Rev. Food Sci. Food Saf."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2017.03.008","article-title":"Nanoemulsion: Concepts, development and applications in drug delivery","volume":"252","author":"Singh","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Karunaratne, N., Pamunuwa, G., and Ranatunga, U. (2017). Introductory Chapter: Microemulsions. Properties and Uses of Microemulsions, Intech.","DOI":"10.5772\/intechopen.68823"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1208\/s12249-011-9742-7","article-title":"Microemulsion-based gel of terbinafine for the treatment of onychomycosis: Optimization of formulation using D-optimal design","volume":"13","author":"Barot","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"ref_157","first-page":"685","article-title":"Physiochemical characterization and release rate studies of solid dispersions of Ketoconazole with Pluronic F127 and PVP K-30","volume":"10","author":"Kumara","year":"2011","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1039\/C6SM02107G","article-title":"Protein diffusion in a bicontinuous microemulsion: Inducing sub-diffusion by tuning the water domain size","volume":"13","author":"Neubauer","year":"2017","journal-title":"Soft Matter"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cocis.2016.02.001","article-title":"The hydrophobic effect","volume":"22","author":"Kronberg","year":"2016","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11743-015-1694-6","article-title":"The Schulman Method of Cosurfactant Titration of the Oil\/Water Interface (Dilution Method): A Review on a Well-Known Powerful Technique in Interfacial Science for Characterization of Water-in-Oil Microemulsions","volume":"18","author":"Bardhan","year":"2015","journal-title":"J. Surfactants Deterg."},{"key":"ref_161","first-page":"499","article-title":"The viscosity behaviour of microemulsions: An overview","volume":"66","author":"Paul","year":"2000","journal-title":"Proc. Indian Natl. Sci. Acad."},{"key":"ref_162","first-page":"4442","article-title":"Microemulsions as antidiabetic drug delivery systems","volume":"3","author":"Sarhan","year":"2012","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0001-8686(98)00063-3","article-title":"Structure, dynamics and transport properties of microemulsions","volume":"78","author":"Moulik","year":"1998","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s11095-013-1063-y","article-title":"Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): The underlying mechanisms for amiodarone and talinolol","volume":"30","author":"Elgart","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.colsurfb.2012.05.019","article-title":"Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides","volume":"100","author":"Bandyopadhyay","year":"2012","journal-title":"Colloids Surf. B. Biointerfaces"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1021\/jp901617g","article-title":"Formation and Characterization of Ordered Bicontinuous Microemulsions","volume":"113","author":"Kogan","year":"2009","journal-title":"J. Phys. Chem."},{"key":"ref_167","first-page":"108164","article-title":"Microemulsion Drug Delivery System: For Bioavailability Enhancement of Ampelopsin","volume":"2012","author":"Solanki","year":"2012","journal-title":"ISRN Pharm."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bfopcu.2013.07.002","article-title":"Formulation consideration and characterization of microemulsion drug delivery system for transnasal administration of carbamazepine","volume":"51","author":"Patel","year":"2013","journal-title":"Bull. Fac. Pharmacy, Cairo Univ."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/03639045.2015.1066799","article-title":"Rheological and textural properties of microemulsion-based polymer gels with indomethacin","volume":"42","author":"Froelich","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4333\/KPS.2010.40.5.305","article-title":"Microemulsion-based Hydrogel Formulation of Itraconazole for Topical Delivery","volume":"40","author":"Lee","year":"2010","journal-title":"J. Pharm. Investig."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ijpharm.2019.02.011","article-title":"Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer","volume":"560","author":"Mojeiko","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1080\/10942912.2018.1485032","article-title":"Microemulsion-based anthocyanin systems: Effect of surfactants, cosurfactants, and its stability","volume":"21","author":"Chen","year":"2018","journal-title":"Int. J. Food Prop."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jps.22307","article-title":"Intranasal clobazam delivery in the treatment of status epilepticus","volume":"100","author":"Florence","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_174","unstructured":"Grumezescu, A.M. (2018). Self-nanoemulsifying drug delivery systems (SNEDDS) and selfmicroemulsifying drug delivery systems (SMEDDS) as lipid nanocarriers for improving dissolution rate and bioavailability of poorly soluble drugs. Lipid Nanocarriers for Drug Targeting, William Andrew Publishing."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/17425247.5.1.119","article-title":"Microemulsions as novel drug carriers: The formation, stability, applications and toxicity","volume":"5","author":"Karasulu","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_176","unstructured":"Jafari, S.M., and McClements, D.J. (2018). Fabrication of Nanoemulsions by Ultrasonication. Nanoemulsions: Formulation, Applications, and Characterization, Academic Press."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.foodres.2016.01.033","article-title":"Nanoemulsion preparation by combining high pressure homogenization and high power ultrasound at low energy densities","volume":"83","author":"Calligaris","year":"2016","journal-title":"Food Res. Int."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jfoodeng.2015.08.012","article-title":"Curcumin-loaded nanoemulsions produced by the emulsion inversion point (EIP) method: An evaluation of process parameters and physico-chemical stability","volume":"169","author":"Borrin","year":"2016","journal-title":"J. Food Eng."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jcis.2019.01.018","article-title":"Nanoemulsion formation by the phase inversion temperature method using polyoxypropylene surfactants","volume":"540","author":"Ren","year":"2019","journal-title":"J. Colloid Interface Sci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nphys3003","article-title":"Nanoemulsions obtained via bubble-bursting at a compound interface","volume":"10","author":"Feng","year":"2014","journal-title":"Nat. Phys."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.3109\/10717544.2016.1162876","article-title":"Systematic development of optimized SNEDDS of artemether with improved biopharmaceutical and antimalarial potential","volume":"23","author":"Tripathi","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3109\/10717544.2014.900154","article-title":"QbD-based systematic development of novel optimized solid self-nanoemulsifying drug delivery systems (SNEDDS) of lovastatin with enhanced biopharmaceutical performance","volume":"22","author":"Beg","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"111423","DOI":"10.1016\/j.colsurfb.2020.111423","article-title":"Particle-stabilized oil-in-water emulsions as a platform for topical lipophilic drug delivery","volume":"197","author":"Hiranphinyophat","year":"2021","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.foodhyd.2015.12.035","article-title":"Nanoemulsion based delivery system for improved bioaccessibility and Caco-2 cell monolayer permeability of green tea catechins","volume":"56","author":"Bhushani","year":"2016","journal-title":"Food Hydrocoll."},{"key":"ref_185","first-page":"832","article-title":"Nanoemulsion for lymphatic absorption: Investigation of fenofibrate nanoemulsion system for lymphatic uptake","volume":"7","author":"Sureshkumar","year":"2015","journal-title":"Int. J. ChemTech Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.2147\/IJN.S259993","article-title":"A non-lipolysis nanoemulsion improved oral bioavailability by reducing the first-pass metabolism of raloxifene, and related absorption mechanisms being studied","volume":"15","author":"Ye","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T.L., Duong, V.A., and Maeng, H.J. (2021). Pharmaceutical formulations with p-glycoprotein inhibitory effect as promising approaches for enhancing oral drug absorption and bioavailability. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071103"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Figueiredo, K.A., Neves, J.K.O., Da Silva, J., De Freitas, R.M., and Carvalho, A.L.M. (2016). Phenobarbital loaded microemulsion: Development, kinetic release and quality control. Brazillian J. Pharm. Sci., 52.","DOI":"10.1590\/S1984-82502016000200003"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"(2018). Alzheimer Association Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 14, 367\u2013429.","DOI":"10.1016\/j.jalz.2018.02.001"},{"key":"ref_190","first-page":"226","article-title":"Pathophysiology and management of alzheimer\u2019s disease: An overview","volume":"7","author":"Thakur","year":"2018","journal-title":"J. Anal. Pharm. Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3389\/fneur.2019.01312","article-title":"New Insights Into the Pathogenesis of Alzheimer\u2019s Disease","volume":"10","author":"Fan","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease","volume":"14","author":"Twohig","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2165\/00003495-200666110-00015","article-title":"Memantine A Review of its Use in Alzheimer\u2019s Disease","volume":"66","author":"Robinson","year":"2006","journal-title":"Drugs"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4236\/wjns.2015.55030","article-title":"Cure for Alzheimer\u2019s Disease","volume":"5","author":"Patnaik","year":"2015","journal-title":"World J. Neurosci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer\u2019s disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3233\/JAD-215065","article-title":"A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer\u2019s Disease","volume":"83","author":"Mukhopadhyay","year":"2021","journal-title":"J. Alzheimers. Dis."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_198","unstructured":"ALZFORUM (2022, January 12). Therapeutics. Available online: https:\/\/www.alzforum.org\/therapeutics."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","article-title":"Modern methods for delivery of drugs across the blood-brain barrier","volume":"64","author":"Chen","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002329900434","article-title":"Blood-brain barrier permeation: Molecular parameters governing passive diffusion","volume":"165","author":"Fischer","year":"1998","journal-title":"J. Membr. Biol."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Pardridge, W.M. (2020). Treatment of alzheimer\u2019s disease and blood-brain barrier drug delivery. Pharmaceuticals, 13.","DOI":"10.3390\/ph13110394"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejpb.2020.01.005","article-title":"Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases","volume":"149","author":"Teixeira","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/10717544.2018.1428243","article-title":"Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer\u2019s disease","volume":"25","author":"Karthivashan","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00688493","article-title":"Uptake of exogenous proteins in mouse olfactory cells","volume":"19","author":"Kristensson","year":"1971","journal-title":"Acta Neuropathol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1021\/acs.molpharmaceut.0c00461","article-title":"Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Blood-Brain Barrier for Effective Treatment of Alzheimer\u2019s Disease","volume":"18","author":"Arora","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_207","first-page":"1838","article-title":"Solid lipid nanoparticles for nose to brain delivery of donepezil: Formulation, optimization by Box\u2013Behnken design, in vitro and in vivo evaluation","volume":"46","author":"Yasir","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"P299","DOI":"10.1016\/j.jalz.2013.05.609","article-title":"Curcumin-donepezil\u2013loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer\u2019s disease model","volume":"9","author":"Sood","year":"2013","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","article-title":"Galantamine-loaded solid\u2013lipid nanoparticles for enhanced brain delivery: Preparation, characterization, in vitro and in vivo evaluations","volume":"23","author":"Misra","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_210","first-page":"CD001191","article-title":"Rivastigmine for Alzheimer\u2019s disease","volume":"2015","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","article-title":"Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration","volume":"452","author":"Yang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_212","first-page":"393","article-title":"Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer\u2019s disease","volume":"8","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3109\/03639045.2010.541262","article-title":"New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations","volume":"37","author":"Mutlu","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_214","unstructured":"Watts, R.L., Standaert, D.G., and Obeso, J.A. (2012). Chapter 10. Epidemiology of Parkinson\u2019s Disease. Movement Disorders, The McGraw-Hill Companies."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"The Non-motor symptoms of Parkinson\u2019 s disease: Diagnosis and management Related papers management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","article-title":"Non-motor symptoms in Parkinson\u2019s disease","volume":"22","author":"Pfeiffer","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"Breteler","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson\u2019s disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1471-1931(00)00028-8","article-title":"Pathophysiology of the basal ganglia in Parkinson\u2019s disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/bs.pbr.2019.11.002","article-title":"What we can learn from iPSC-derived cellular models of Parkinson\u2019s disease","volume":"252","author":"Caiazza","year":"2020","journal-title":"Prog. Brain Res."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41401-020-0365-y","article-title":"Recent advances in dopaminergic strategies for the treatment of Parkinson\u2019s disease","volume":"41","author":"Mao","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtice.2018.03.028","article-title":"Current development of nanocarrier delivery systems for Parkinson\u2019s disease pharmacotherapy","volume":"87","author":"Kuo","year":"2018","journal-title":"J. Taiwan Inst. Chem. Eng."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.25634.1","article-title":"Recent developments in the treatment of Parkinson\u2019s Disease","volume":"9","author":"Stoker","year":"2020","journal-title":"F1000Research"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/17425247.2016.1178237","article-title":"Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases","volume":"13","author":"Cacciatore","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"120881","DOI":"10.1016\/j.ijpharm.2021.120881","article-title":"Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson\u2019s disease","volume":"606","author":"Uppuluri","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s11095-007-9514-y","article-title":"Solid lipid nanoparticles as delivery systems for bromocriptine","volume":"25","author":"Esposito","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/02652040010018119","article-title":"Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles","volume":"18","author":"Demirel","year":"2001","journal-title":"J. Microencapsul."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/jps.22285","article-title":"Oral apomorphine delivery from solid lipid nanoparticleswith different monostearate emulsifiers: Pharmacokinetic and behavioral evaluations","volume":"100","author":"Tsai","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10717544.2012.752421","article-title":"Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: Application of factorial design approach","volume":"20","author":"Pardeshi","year":"2013","journal-title":"Drug Deliv."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JPD-181331","article-title":"Gene therapy for Parkinson\u2019s disease, an update","volume":"8","author":"Axelsen","year":"2018","journal-title":"J. Parkinsons. Dis."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0079-6123(10)84013-0","article-title":"Neurotrophic factor therapy for Parkinson\u2019s disease","volume":"184","author":"Rangasamy","year":"2010","journal-title":"Prog. Brain Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1083\/jcb.201009136","article-title":"Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin","volume":"192","author":"Bespalov","year":"2011","journal-title":"J. Cell Biol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.nano.2013.10.009","article-title":"Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats","volume":"10","author":"Zhao","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12035-017-0728-7","article-title":"Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson\u2019s disease","volume":"55","author":"Hernando","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_236","first-page":"25","article-title":"Emerging Nanotechnology for Treatment of Alzheimer\u2019s and Parkinson\u2019s Disease","volume":"9","author":"Li","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1039\/D0NA00688B","article-title":"Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by \u03b1-synuclein aggregates","volume":"2","author":"Piersimoni","year":"2020","journal-title":"Nanoscale Adv."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fncel.2018.00529","article-title":"Idebenone Alleviates Neuroinflammation and Modulates Microglial Polarization in LPS-Stimulated BV2 Cells and MPTP-Induced Parkinson\u2019s Disease Mice","volume":"12","author":"Hayley","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/rej.2017.1959","article-title":"Attenuation of oxidative damage by coenzyme Q10 loaded nanoemulsion through oral route for the management of Parkinson\u2019s disease","volume":"21","author":"Gupta","year":"2018","journal-title":"Rejuvenation Res."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijpharm.2017.12.047","article-title":"Stability, biocompatibility and antioxidant activity of PEG-modified liposomes containing resveratrol","volume":"538","author":"Caddeo","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.21037\/apm-19-426","article-title":"Protective effects of resveratrol liposomes on mitochondria in substantia nigra cells of parkinsonized rats","volume":"10","author":"Chen","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1089\/rej.2017.2035","article-title":"Selegiline Nanoformulation in Attenuation of Oxidative Stress and Upregulation of Dopamine in the Brain for the Treatment of Parkinson\u2019s Disease","volume":"21","author":"Kumar","year":"2018","journal-title":"Rejuvenation Res."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"121131","DOI":"10.1016\/j.ijpharm.2021.121131","article-title":"Lipid nanocarrier of selegiline augmented anti-Parkinson\u2019s effect via P-gp modulation using quercetin","volume":"609","author":"Qamar","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Mursaleen, L., Noble, B., Somavarapu, S., and Zariwala, M.G. (2021). Micellar nanocarriers of hydroxytyrosol are protective against parkinson\u2019s related oxidative stress in an in vitro hcmec\/d3-sh-sy5y co-culture system. Antioxidants, 10.","DOI":"10.3390\/antiox10060887"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"104506","DOI":"10.1016\/j.jff.2021.104506","article-title":"Potential role of hydroxytyrosol in neuroprotection","volume":"82","author":"Chen","year":"2021","journal-title":"J. Funct. Foods"},{"key":"ref_246","first-page":"1492","article-title":"Pharmacokinetics and metabolism of hydroxytyrosol, a natural antioxidant from olive oil","volume":"29","author":"Manna","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jns.2019.10.1271","article-title":"Fabrication of solid lipid nanoparticles containing vitexin protects dopaminergic neurons against 6-hydroxydopamine induced Parkinson\u2019s disease model via altered the genetic backgrounds","volume":"405","author":"Rahman","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fmedt.2020.602236","article-title":"Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain","volume":"2","author":"Pardridge","year":"2020","journal-title":"Front. Med. Technol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/s41598-020-63894-9","article-title":"Liposomal drug delivery of Aphanamixis polystachya leaf extracts and its neurobehavioral activity in mice model","volume":"10","author":"Shariare","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"469679","DOI":"10.1155\/2011\/469679","article-title":"Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer\u2019s Disease and Parkinson\u2019s Disease)","volume":"2011","author":"Spuch","year":"2011","journal-title":"J. Drug Deliv."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: A Delphi consensus study","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neuint.2017.08.001","article-title":"Resveratrol loaded solid lipid nanoparticles attenuate mitochondrial oxidative stress in vascular dementia by activating Nrf2\/HO-1 pathway","volume":"112","author":"Yadav","year":"2018","journal-title":"Neurochem. Int."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"100029","DOI":"10.1016\/j.crbeha.2021.100029","article-title":"Neuroprotective effects of curcumin loaded solid lipid nanoparticles on homocysteine induced oxidative stress in vascular dementia","volume":"2","author":"Prathipati","year":"2021","journal-title":"Curr. Res. Behav. Sci."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3109\/03639045.2010.516264","article-title":"Formulation development and in vitro evaluation of didanosine-loaded nanostructured lipid carriers for the potential treatment of AIDS dementia complex","volume":"37","author":"Shegokar","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08982104.2010.539186","article-title":"Evaluation of the in vitro differential protein adsorption patterns of didanosine-loaded nanostructured lipid carriers (NLCs) for potential targeting to the brain","volume":"21","author":"Kasongo","year":"2011","journal-title":"J. Liposome Res."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"104794","DOI":"10.1016\/j.chemphyslip.2019.104794","article-title":"Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia","volume":"224","author":"Chauhan","year":"2019","journal-title":"Chem. Phys. Lipids"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/10837450.2019.1694037","article-title":"Lipid\u2013drug conjugates and associated carrier strategies for enhanced antiretroviral drug delivery","volume":"25","author":"Takalani","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10717544.2013.844744","article-title":"Development and characterization of PLGA nanoparticles as delivery systems of a prodrug of zidovudine obtained by its conjugation with ursodeoxycholic acid","volume":"21","author":"Dalpiaz","year":"2014","journal-title":"Drug Deliv."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"119678","DOI":"10.1016\/j.biomaterials.2019.119678","article-title":"Self-assembly hollow manganese Prussian white nanocapsules attenuate Tau-related neuropathology and cognitive decline","volume":"231","author":"Cai","year":"2020","journal-title":"Biomaterials"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"35045","DOI":"10.1021\/acsami.6b13052","article-title":"Endogenous Polysialic Acid Based Micelles for Calmodulin Antagonist Delivery against Vascular Dementia","volume":"8","author":"Wang","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.12059","article-title":"Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer\u2019s disease","volume":"124","author":"Choi","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Sipos, B., Szab\u00f3-R\u00e9v\u00e9sz, P., Cs\u00f3ka, I., Pallagi, E., Dob\u00f3, D.G., B\u00e9lteky, P., K\u00f3nya, Z., De\u00e1k, \u00c1., Janov\u00e1k, L., and Katona, G. (2020). Quality by design based formulation study of meloxicam-loaded polymeric micelles for intranasal administration. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12080697"},{"key":"ref_263","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG) (2022, February 22). Epilepsy: Overview, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK343313\/."},{"key":"ref_264","unstructured":"Bromfield, E.B., Cavazos, J.E., and Sirven, J.I. (2006). Basic Mechanisms Underlying Seizures and Epilepsy. An Introduction to Epilepsy, American Epilepsy Society."},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Ahmad, N., Ahmad, R., Qatifi, A., Alessa, M., Hajji, H., and Sarafroz, M. (2020). A bioanalytical UHPLC based method used for the quantification of Thymoquinone-loaded-PLGA-nanoparticles in the treatment of epilepsy. BMC Chem., 14.","DOI":"10.1186\/s13065-020-0664-x"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ultsonch.2013.10.013","article-title":"Skin permeation of d-limonene-based nanoemulsions as a transdermal carrier prepared by ultrasonic emulsification","volume":"21","author":"Lu","year":"2014","journal-title":"Ultrason. Sonochem."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s13346-012-0126-7","article-title":"Development of carbamazepine transnasal microemulsion for treament of epilepsy","volume":"3","author":"Porecha","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajps.2013.07.008","article-title":"Preparation and evaluation of transnasal microemulsionof carbamazepine","volume":"8","author":"Acharya","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","article-title":"The transport of antiepileptic drugs by P-glycoprotein","volume":"64","author":"Zhang","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_270","first-page":"51","article-title":"Selecting surfactants for the maximum inhibition of the activity of the multi drug resistance efflux pump transporter, P-glycoprotein: Conceptual development","volume":"1","author":"Prakash","year":"2010","journal-title":"J. Excipients Food Chem."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"119486","DOI":"10.1016\/j.ijpharm.2020.119486","article-title":"Intranasal delivery of topiramate nanoemulsion: Pharmacodynamic, pharmacokinetic and brain uptake studies","volume":"585","author":"Patel","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0378-5173(95)04416-7","article-title":"In vitro and in vivo nasal mucoadhesion of some water-soluble polymers","volume":"134","author":"Nakamura","year":"1996","journal-title":"Int. J. Pharm."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cne.902940212","article-title":"Ultrastructure substance P- and CGRP-immunoreactive nerve fibres in the nasal epithelium of rodents","volume":"294","author":"Finger","year":"1990","journal-title":"J. Comp. Neurol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/187221108784534072","article-title":"Potential of microemulsions in drug delivery and therapeutics: A patient review","volume":"2","author":"Bali","year":"2008","journal-title":"Recent Patents Drug Deliv. Formul."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.xphs.2018.04.007","article-title":"Superparamagnetic Iron Oxide\u2013Loaded Lipid Nanocarriers Incorporated in Thermosensitive In Situ Gel for Magnetic Brain Targeting of Clonazepam","volume":"107","author":"Abbas","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/21691401.2016.1160407","article-title":"Development and characterization of embelin-loaded nanolipid carriers for brain targeting","volume":"45","author":"Sharma","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/17425247.2014.945416","article-title":"Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: In vitro characterization and in vivo efficacy in epilepsy","volume":"12","author":"Alam","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_278","first-page":"363","article-title":"Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: In vivo pharmacodynamic studies using rat electroshock model","volume":"6","author":"Eskandari","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ijpharm.2011.12.009","article-title":"Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting","volume":"423","author":"Tsai","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.04.049","article-title":"Effect of Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia-reperfusion in rats","volume":"489","author":"Liu","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biomaterials.2013.09.093","article-title":"Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles","volume":"35","author":"Lu","year":"2014","journal-title":"Biomaterials"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0361-9230(00)00354-3","article-title":"Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine","volume":"53","author":"Nemes","year":"2000","journal-title":"Brain Res. Bull."},{"key":"ref_284","first-page":"623","article-title":"In vitro-in vivo correlation of the pharmacokinetics of vinpocetine","volume":"53","author":"Veres","year":"2001","journal-title":"Pol. J. Pharmacol."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijpharm.2014.02.013","article-title":"A novel oral delivery system consisting in \u201cdrug-in cyclodextrin-in nanostructured lipid carriers\u201d for poorly water-soluble drug: Vinpocetine","volume":"465","author":"Lin","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/10837450.2012.734513","article-title":"Brain targeted solid lipid nanoparticles for brain ischemia: Preparation and in vitro characterization","volume":"18","author":"Morsi","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.neuint.2010.07.012","article-title":"Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: Involvement of neuroinflammation","volume":"57","author":"Bernardi","year":"2010","journal-title":"Neurochem. Int."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1007\/s12274-021-3413-8","article-title":"Systemic delivery of microRNA for treatment of brain ischemia","volume":"14","author":"Liu","year":"2021","journal-title":"Nano Res."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"8197","DOI":"10.7150\/thno.58947","article-title":"Early administration of MPC-n(IVIg) selectively accumulates in ischemic areas to protect inflammation-induced brain damage from ischemic stroke","volume":"11","author":"Jin","year":"2021","journal-title":"Theranostics"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7150\/thno.18219","article-title":"Edaravone-encapsulated agonistic micelles rescue ischemic brain tissue by tuning blood-brain barrier permeability","volume":"7","author":"Jin","year":"2017","journal-title":"Theranostics"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1808361","DOI":"10.1002\/adma.201808361","article-title":"Microthrombus-Targeting Micelles for Neurovascular Remodeling and Enhanced Microcirculatory Perfusion in Acute Ischemic Stroke","volume":"31","author":"Lu","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"120681","DOI":"10.1016\/j.biomaterials.2021.120681","article-title":"Treatment of ischemic neuronal death by introducing brain-derived neurotrophic factor mRNA using polyplex nanomicelle","volume":"270","author":"Fukushima","year":"2021","journal-title":"Biomaterials"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"S982","DOI":"10.1080\/21691401.2018.1523181","article-title":"Amelioration of ischaemia reperfusion-induced cerebral injury in mice by liposomes containing Allium cepa fraction administered intranasally","volume":"46","author":"Singh","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainresbull.2019.07.015","article-title":"Liposomes for drug delivery in stroke","volume":"152","author":"Bruch","year":"2019","journal-title":"Brain Res. Bull."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrneurol.2012.76","article-title":"Nanotechnology\u2014Novel therapeutics for CNS disorders","volume":"8","author":"Srikanth","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.addr.2012.01.004","article-title":"Challenges in drug delivery to tumors of the central nervous system: An overview of pharmacological and surgical considerations","volume":"64","author":"Serwer","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijpharm.2007.12.013","article-title":"Solid lipid nanoparticles of temozolomide: Potential reduction of cardial and nephric toxicity","volume":"355","author":"Huang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2006.02.014","article-title":"Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition","volume":"112","author":"Lamprecht","year":"2006","journal-title":"J. Control. Release"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/1535-7163.MCT-06-0289","article-title":"A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats","volume":"5","author":"Garcion","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2012.09.054","article-title":"Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies","volume":"439","author":"Martins","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ejpb.2013.08.011","article-title":"Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration","volume":"85","author":"Martins","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2004.07.006","article-title":"Paclitaxel nanoparticles for the potential treatment of brain tumors","volume":"99","author":"Koziara","year":"2004","journal-title":"J. Control. Release"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/phrs.2000.0695","article-title":"Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats","volume":"42","author":"Cavalli","year":"2000","journal-title":"Pharmacol. Res."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/phrs.1999.0509","article-title":"Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN)","volume":"40","author":"Zara","year":"1999","journal-title":"Pharmacol. Res."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jconrel.2008.05.027","article-title":"Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas","volume":"130","author":"Allard","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1039\/C9TB02700A","article-title":"Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: Therapeutic promise for combating glioblastoma","volume":"8","author":"Saha","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/10837450.2016.1189933","article-title":"Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box\u2013Behnken design","volume":"22","author":"Emami","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1021\/acs.molpharmaceut.6b00586","article-title":"Brain Targeting of Temozolomide via the Intranasal Route Using Lipid-Based Nanoparticles: Brain Pharmacokinetic and Scintigraphic Analyses","volume":"13","author":"Khan","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3109\/10717544.2015.1064186","article-title":"Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy","volume":"23","author":"Song","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1080\/10717544.2016.1189465","article-title":"Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: Which kind of drug delivery system is better for glioblastoma chemotherapy?","volume":"23","author":"Qu","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1166\/jnn.2011.4235","article-title":"Development and evaluation of nanostructured lipid carriers of cytarabine for treatment of meningeal leukemia","volume":"11","author":"Sharma","year":"2011","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/1042819032000159861","article-title":"Problems related to resistance to cytarabine in acute myeloid leukemia","volume":"45","author":"Cros","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_313","first-page":"54","article-title":"Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine","volume":"28","author":"Capizzi","year":"1991","journal-title":"Semin. Hematol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3109\/10717544.2015.1058434","article-title":"Vincristine and temozolomide combined chemotherapy for the treatment of glioma: A comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery","volume":"23","author":"Wu","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3109\/10717544.2015.1038857","article-title":"Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy","volume":"23","author":"Chen","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fphar.2020.00261","article-title":"Pharmacotherapy of Alzheimer\u2019s Disease: Seeking Clarity in a Time of Uncertainty","volume":"11","author":"Yahaya","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond","volume":"35","author":"Klein","year":"2021","journal-title":"CNS Drugs"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2003.07.003","article-title":"Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059","volume":"100","author":"Green","year":"2003","journal-title":"Pharmacol. Ther."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/836\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:51:52Z","timestamp":1760136712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/4\/836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":318,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["pharmaceutics14040836"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14040836","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]}}}